ArriVent BioPharma, Inc.
AVBP
$20.82
-$0.35-1.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 952.00K | 866.00K | 765.00K | 625.00K | 319.00K |
| Change in Net Operating Assets | 3.53M | 3.35M | 2.02M | -1.84M | 5.96M |
| Cash from Operations | -16.15M | -16.35M | -19.09M | -18.63M | -14.91M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -192.47M | -- | -- | -- | 25.00M |
| Cash from Investing | -192.47M | -- | -- | -- | 25.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 55.00K | 531.00K | 363.00K | 185.63M | 285.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1.34M |
| Cash from Financing | 55.00K | 531.00K | 363.00K | 185.63M | -1.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -208.56M | -15.81M | -18.72M | 167.00M | 9.03M |